Economics at your fingertips  

The stock market's valuationof R&D externalities

Hironobu Miyazaki and Hiroyuki Aman

Applied Financial Economics Letters, 2008, vol. 4, issue 5, 369-373

Abstract: R&D, particularly basic research, is generally considered as a public good. It provides positive externalities to other firms. This article investigates rival firms' stock-price responses to an increase in the R&D expenditures of a firm. Examining firms in the pharmaceutical industry, we found that the market valuations of some rival firms benefit from R&D externalities. Moreover, the cross-sectional analysis indicated that R&D-intensive firms benefit immensely from them. From this result, investors might assess that these firms have the full potential to absorb new R&D knowledge.

Date: 2008
References: Add references at CitEc
Citations Track citations by RSS feed

Downloads: (external link) ... 40C6AD35DC6213A474B5 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Ordering information: This journal article can be ordered from

Access Statistics for this article

Applied Financial Economics Letters is currently edited by Mark Taylor

More articles in Applied Financial Economics Letters from Taylor and Francis Journals
Series data maintained by Chris Longhurst ().

Page updated 2017-10-21
Handle: RePEc:taf:apfelt:v:4:y:2008:i:5:p:369-373